Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gent – page 33

899 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance
899
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

899 trials in Gent

Open in trial search

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Gastrooesophageal cancer

Not yet recruiting

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:UZ Leuven

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:BioNTech SE

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Coronary artery disease

Not yet recruiting

A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

Head and neck cancer

Not yet recruiting

Study of ezabenlimab in patients with locally advanced head and neck cancer who have remaining signs of disease after chemoradiotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ezabenlimab
  • Sponsor:Cliniques Universitaires Saint-Luc

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

  • Influenza vaccine studies for adults 65+
  • RSV vaccine development
  • Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

  • Nasal decongestant dependency treatment
  • Chronic rhinosinusitis management
  • Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

  • Primary biliary cholangitis treatment
  • Psoriasis therapies
  • Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.